Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
Recruiting now · Phase 2
Conditions studied: High Grade Glioma, CNS Tumor
In brief
This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.
Key facts
- Study ID
- NCT06528691
- Run by
- St. Jude Children's Research Hospital
- People needed
- 52
- Starts
- 2026-05-01
- Expected to finish
- 2032-11-01
- Last updated by the study team
- 2026-05-13
Who can join
Age: any, up to 3. Sex: any. Healthy volunteers: not accepted.
Where it is running
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States (enrolling)
- Hospital de Câncer de Barretos — Barretos, São Paulo, Brazil (enrolling)
- GRAACC Hospital (Grupo de Apoio ao Adolescente e à Criança com Câncer) — São Paulo, Brazil (enrolling)
- Hospital Santa Marcelina — São Paulo, Brazil (enrolling)
- King Hussein Cancer Center — Amman, Jordan (enrolling)
- Instituto Nacional de Enfermedades Neoplásicas — Lima, Peru (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.